KMT Hepatech to Partner at BIO International Convention

Edmonton, May 30, 2016 – KMT Hepatech, Inc., a Canadian biotechnology company offering in vivo research services utilizing proprietary KMT MouseTM (uPA/SCID mouse model with stable human hepatocytes engraftment of up to 95 per cent), announced that representative from the company will be participating in the BIO International Convention. Dr. Svetlana Sapelnikova (Director, Marketing / Business Development) will take part in the prescheduled meetings at BIO International convention held June 6‐9, 2016 in San Francisco, California.

Companies or individuals attending BIO One‐on‐One Partnering can schedule meeting with KMT Hepatech visiting http://convention.bio.org/partner/ (registration required).

For companies or individuals not participating in partnering meetings, KMT Hepatech will be coexhibiting within Canada Pavilion in booth 5944 (BioAlberta section). For the exhibition hall schedule, visit http://convention.bio.org/exhibit/

For more details on KMT Hepatech services visit http://kmthepatech.com/en/Services.aspx

About KMT Hepatech, Inc.: A private company providing in vivo research services utilizing proprietary
platform technology of the chimeric mouse model with highly humanized liver. Due to the expanding
interest in the humanized liver mouse model across a wide range of drug development fields, the
company now offers services in infectious diseases (hepatitis, malaria), early assessment of human
hepatotoxicity and characterization of human‐type drug metabolism.

Contact:
Dr. Svetlana Sapelnikova
KMT Hepatech, Inc.
+1 (780) 641 1917
www.kmthepatech.com